vs
Side-by-side financial comparison of Vertiv Holdings Co (VRT) and Zoetis (ZTS). Click either name above to swap in a different company.
Vertiv Holdings Co is the larger business by last-quarter revenue ($2.6B vs $2.4B, roughly 1.1× Zoetis). Zoetis runs the higher net margin — 25.3% vs 14.7%, a 10.5% gap on every dollar of revenue. On growth, Vertiv Holdings Co posted the faster year-over-year revenue change (30.1% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $652.8M). Over the past eight quarters, Vertiv Holdings Co's revenue compounded faster (16.5% CAGR vs 4.4%).
Vertiv is an American multinational provider of critical infrastructure and services for data centers, communication networks, and commercial and industrial environments.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
VRT vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.6B | $2.4B |
| Net Profit | $390.1M | $603.0M |
| Gross Margin | 37.7% | 70.2% |
| Operating Margin | — | 31.9% |
| Net Margin | 14.7% | 25.3% |
| Revenue YoY | 30.1% | 3.0% |
| Net Profit YoY | 137.1% | 3.8% |
| EPS (diluted) | $0.99 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.9B | $2.4B | ||
| Q3 25 | $2.7B | $2.4B | ||
| Q2 25 | $2.6B | $2.5B | ||
| Q1 25 | $2.0B | $2.2B | ||
| Q4 24 | $2.3B | $2.3B | ||
| Q3 24 | $2.1B | $2.4B | ||
| Q2 24 | $2.0B | $2.4B |
| Q1 26 | $390.1M | — | ||
| Q4 25 | $445.6M | $603.0M | ||
| Q3 25 | $398.5M | $721.0M | ||
| Q2 25 | $324.2M | $718.0M | ||
| Q1 25 | $164.5M | $631.0M | ||
| Q4 24 | $147.0M | $581.0M | ||
| Q3 24 | $176.6M | $682.0M | ||
| Q2 24 | $178.1M | $624.0M |
| Q1 26 | 37.7% | — | ||
| Q4 25 | 38.9% | 70.2% | ||
| Q3 25 | 37.8% | 71.5% | ||
| Q2 25 | 34.0% | 73.6% | ||
| Q1 25 | 33.7% | 72.0% | ||
| Q4 24 | 37.1% | 69.5% | ||
| Q3 24 | 36.5% | 70.6% | ||
| Q2 24 | 38.0% | 71.7% |
| Q1 26 | — | — | ||
| Q4 25 | 20.1% | 31.9% | ||
| Q3 25 | 19.3% | 37.0% | ||
| Q2 25 | 16.8% | 36.7% | ||
| Q1 25 | 14.3% | 36.5% | ||
| Q4 24 | 19.5% | 31.6% | ||
| Q3 24 | 17.9% | 36.6% | ||
| Q2 24 | 17.2% | 33.0% |
| Q1 26 | 14.7% | — | ||
| Q4 25 | 15.5% | 25.3% | ||
| Q3 25 | 14.9% | 30.0% | ||
| Q2 25 | 12.3% | 29.2% | ||
| Q1 25 | 8.1% | 28.4% | ||
| Q4 24 | 6.3% | 25.1% | ||
| Q3 24 | 8.5% | 28.6% | ||
| Q2 24 | 9.1% | 26.4% |
| Q1 26 | $0.99 | — | ||
| Q4 25 | $1.14 | $1.37 | ||
| Q3 25 | $1.02 | $1.63 | ||
| Q2 25 | $0.83 | $1.61 | ||
| Q1 25 | $0.42 | $1.41 | ||
| Q4 24 | $0.38 | $1.29 | ||
| Q3 24 | $0.46 | $1.50 | ||
| Q2 24 | $0.46 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5B | — |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $4.2B | $3.3B |
| Total Assets | $13.4B | $15.5B |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.5B | — | ||
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.4B | $2.1B | ||
| Q2 25 | $1.6B | $1.4B | ||
| Q1 25 | $1.5B | $1.7B | ||
| Q4 24 | $1.2B | $2.0B | ||
| Q3 24 | $908.7M | $1.7B | ||
| Q2 24 | $579.7M | $1.6B |
| Q1 26 | $0 | — | ||
| Q4 25 | $2.9B | — | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $2.9B | — | ||
| Q1 25 | $2.9B | — | ||
| Q4 24 | $2.9B | — | ||
| Q3 24 | $2.9B | — | ||
| Q2 24 | $2.9B | — |
| Q1 26 | $4.2B | — | ||
| Q4 25 | $3.9B | $3.3B | ||
| Q3 25 | $3.5B | $5.4B | ||
| Q2 25 | $3.1B | $5.0B | ||
| Q1 25 | $2.7B | $4.7B | ||
| Q4 24 | $2.4B | $4.8B | ||
| Q3 24 | $1.8B | $5.2B | ||
| Q2 24 | $1.5B | $5.0B |
| Q1 26 | $13.4B | — | ||
| Q4 25 | $12.2B | $15.5B | ||
| Q3 25 | $10.8B | $15.2B | ||
| Q2 25 | $10.4B | $14.5B | ||
| Q1 25 | $9.5B | $14.1B | ||
| Q4 24 | $9.1B | $14.2B | ||
| Q3 24 | $8.9B | $14.4B | ||
| Q2 24 | $8.1B | $14.2B |
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.83× | — | ||
| Q2 25 | 0.93× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.20× | — | ||
| Q3 24 | 1.62× | — | ||
| Q2 24 | 1.91× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $893.0M |
| Free Cash FlowOCF − Capex | $652.8M | $732.0M |
| FCF MarginFCF / Revenue | 24.6% | 30.7% |
| Capex IntensityCapex / Revenue | 4.2% | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $2.3B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $978.9M | $893.0M | ||
| Q3 25 | $508.7M | $938.0M | ||
| Q2 25 | $322.9M | $486.0M | ||
| Q1 25 | $303.3M | $587.0M | ||
| Q4 24 | $425.2M | $905.0M | ||
| Q3 24 | $378.2M | $951.0M | ||
| Q2 24 | $378.4M | $502.0M |
| Q1 26 | $652.8M | — | ||
| Q4 25 | $885.6M | $732.0M | ||
| Q3 25 | $463.5M | $805.0M | ||
| Q2 25 | $277.9M | $308.0M | ||
| Q1 25 | $266.8M | $438.0M | ||
| Q4 24 | $364.5M | $689.0M | ||
| Q3 24 | $341.8M | $784.0M | ||
| Q2 24 | $344.3M | $370.0M |
| Q1 26 | 24.6% | — | ||
| Q4 25 | 30.8% | 30.7% | ||
| Q3 25 | 17.3% | 33.5% | ||
| Q2 25 | 10.5% | 12.5% | ||
| Q1 25 | 13.1% | 19.7% | ||
| Q4 24 | 15.5% | 29.7% | ||
| Q3 24 | 16.5% | 32.8% | ||
| Q2 24 | 17.6% | 15.7% |
| Q1 26 | 4.2% | — | ||
| Q4 25 | 3.2% | 6.7% | ||
| Q3 25 | 1.7% | 5.5% | ||
| Q2 25 | 1.7% | 7.2% | ||
| Q1 25 | 1.8% | 6.7% | ||
| Q4 24 | 2.6% | 9.3% | ||
| Q3 24 | 1.8% | 7.0% | ||
| Q2 24 | 1.7% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | 2.20× | 1.48× | ||
| Q3 25 | 1.28× | 1.30× | ||
| Q2 25 | 1.00× | 0.68× | ||
| Q1 25 | 1.84× | 0.93× | ||
| Q4 24 | 2.89× | 1.56× | ||
| Q3 24 | 2.14× | 1.39× | ||
| Q2 24 | 2.12× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VRT
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
